Physician profile
Robert B Cooper
NPI 1558704403
$1,703.65
in general payments reported to CMS, 2019-2025
21 companies · $395 in 2025
The $395 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $164 · 2020: $213 · 2021: $215 · 2022: $236 · 2023: $253 · 2024: $228 · 2025: $395.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $875.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $875.36 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $489.00 | 2020-2025 | Rinvoq, Linzess, Viberzi |
| Celgene Corporation | $172.05 | 2021-2023 | Zeposia |
| Janssen Biotech, INC. | $132.81 | 2021-2024 | Tremfya |
| Gilead Sciences, INC. | $110.88 | 2019-2023 | |
| Boston Scientific Corporation | $106.95 | 2019-2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $105.01 | 2019-2024 | Trulance |
| Regeneron Healthcare Solutions, INC. | $95.83 | 2022-2025 | Dupixent |
| Qol Medical, LLC | $88.56 | 2019-2024 | Sucraid, Sucraid |
| Takeda Pharmaceuticals U.S.A., INC. | $66.90 | 2024-2025 | Entyvio, Eohilia |
| Ardelyx, INC. | $61.96 | 2023-2025 | Ibsrela |
| Pfizer INC. | $35.77 | 2019 | |
| Braintree Laboratories, INC. | $34.76 | 2022 | |
| Ipsen Biopharmaceuticals, INC | $29.57 | 2025 | Iqirvo |
| Merck Sharp & Dohme LLC | $27.11 | 2023-2024 | Dificid, Zerbaxa, Zinplava |
| Aimmune Therapeutics, INC. | $26.29 | 2024 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Phathom Pharmaceuticals, INC. | $24.95 | 2024 | Voquezna |
| Nestle Healthcare Nutrition INC. | $24.69 | 2023 | |
| Redhill Biopharma INC. | $19.72 | 2021 | |
| Novo Nordisk INC | $19.34 | 2025 | Wegovy |
| Recordati_rare_diseases_inc. | $19.22 | 2025 | Panhematin |
| Ironwood Pharmaceuticals, INC | $12.28 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Cooper listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.